Mutant xylan biosynthetic enzymes capable of dominant suppression of xylan biosynthesis
The present invention provides for a polypeptide capable of dominant suppression of a first naturally occurring IRX10, wherein the polypeptide comprises an amino acid sequence having at least 70% identity as compared to a second naturally occurring IRX10 wherein the polypeptide comprises one or more of the conserved amino acid indicated in FIG. 2 substituted with a different amino acid residue.
1. A non-naturally occurring nucleic acid encoding a mutant polypeptide operably linked to a heterologous promoter, wherein the mutant polypeptide exhibits dominant suppression of the naturally occurring IRX10 polypeptide as set forth in SEQ ID NO: 1, wherein the mutant polypeptide comprises one or more of the following mutations in the amino acid sequence as set forth in SEQ ID NO: 1: the histidine at position 146 of SEQ ID NO: 1 is substituted with the aspartate amino acid residue, the cysteine at position 278 of SEQ ID NO: 1 is substituted with the alanine amino acid residue, the glycine at position 283 of SEQ ID NO: 1 is substituted with the aspartate amino acid residue, and the glutamic acid at position 293 of SEQ ID NO: 1 is substituted with the glutamine amino acid residue,
and wherein overexpression of said mutant polypeptide in a plant reduces xylan biosynthesis in said plant.
2. A host cell comprising the non-naturally occurring nucleic acid of claim 1 .
3. A plant transformed with the non-naturally occurring nucleic acid of claim 1 .
4. A method of reducing xylan biosynthesis in a plant, comprising: (a) transforming a plant with the non-naturally occurring nucleic acid of claim 2 , and (b) culturing or growing the transformed plant for overexpression of the non-naturally occurring nucleic acid encoding the mutant polypeptide in said transformed plant to reduce biosynthesis of xylan in the transformed plant as compared to a corresponding control plant of the same plant species lacking the non-naturally occurring nucleic acid and grown under similar growth conditions.
5. The method of claim 4 , wherein the heterologous promoter is a constitutive promoter.
6. The method of claim 4 , wherein the heterologous promoter is an inducible promoter.
7. The method of claim 4 , wherein the heterologous promoter is a tissue specific promoter.
8. The method of claim 7 , wherein the tissue specific promoter is a vessel specific promoter.
9. The method of claim 7 , wherein the tissue specific promoter is a secondary wall specific promoter.
10. The method of claim 4 , wherein the glutamic acid at position 293 of SEQ ID NO: 1 is substituted with the glutamine amino acid residue in the mutant polypeptide.
11. The non-naturally occurring nucleic acid of claim 1 , wherein the glycine at position 283 of SEQ ID NO: 1 is substituted with the aspartate amino acid residue in the mutant polypeptide.